Mon, Jul 14, 2014, 8:07 AM EDT - U.S. Markets open in 1 hr 23 mins

Recent

% | $
Quotes you view appear here for quick access.

Genetic Technologies Limited Message Board

  • einstock einstock Apr 27, 2011 4:20 AM Flag

    GENE'S Brevagen Gets CLIA Certification

    This announcement should start to give Genetic Technologies exposure to the US and World investing community.

    Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has gained certification of its Australian
    laboratory under the US Clinical Laboratories Improvements Amendments (CLIA) (42 U.S.C. § 263a)
    regulated by the Centers for Medicare and Medicaid (CMS). The certification was issued by the CMS
    central office which is responsible for approving non‐US laboratories.

    This certification is the culmination of preparations required for the US launch of the BREVAGenTM
    breast cancer test. BREVAGenTM is a test that informs clinicians about their patients’ individual, nonfamilial,
    sporadic risk of breast cancer. This product fulfils an unmet need by better classifying
    women at moderate risk of breast cancer who would potentially benefit from preventive therapy or
    more intensive monitoring.

    This a very strong statement.

    "BREVAGen™ is the first in a series of products in GTG's anticipated expansion of its oncology and cancer management test portfolio and the Company is all set for commercial roll out.
    1. "series of products"
    2. "all set for commercial roll out"


    http://www.prnewswire.com/news-releases/genetic-technologies-secures-us-approval-for-launch-of-brevagen-breast-cancer-risk-test-120744789.html (full story)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • VICTORIA, Australia, April 26, 2011 /PRNewswire/ -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has gained certification of its Australian laboratory under the US Clinical Laboratories Improvements Amendments (CLIA) (42 U.S.C. section 263a) regulated by the Centers for Medicare and Medicaid (CMS). The certification was issued by the CMS central office which is responsible for approving non-US laboratories.

      This will leads this golden stock atleast 10 $ soon........
      I was shouting when it was 2.20 lst month to buy how much u can brothers...chk my old posts

    • holey smokes!!!!!!!

      Launch preparations for BREVAGen™ are nearing completion and the Company expects to offer the test to US physicians and their patients in coming weeks

 
GENE
1.06+0.01(+0.95%)Jul 11 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.